Nucleotide Analogues

PreclinicalSmall molecule

XXiangya Hospital of Central South University

Nucleotide Analogues is one of 27 small molecule programs targeting Hepatitis B. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

Hepatitis BPreclinical

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

3 2

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 3

Measles Vaccine

GSK

Phase 3

1 4

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

4 5

Hexaxim

Sanofi

Phase 3

1 6

Vemlidy

Gilead

Preclinical

8 7

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

15 8

Quinvaxem

CCrucell Holland BV

Phase 3

1 9

Henogen HB Vaccine

HHenogen

Phase 3

1 10

Rituxan

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Recruiting

Hepatitis B

NCT06746701

Clinical

Trials by Indication[1]

Hepatitis B1 trial

Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.

Recruiting·XXiangya Hospital of Central South University··NCT06746701·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nucleotide Analogues. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nucleotide Analogues compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nucleotide Analogues. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXiangya Hospital of Central South University

Nucleotide Analogues

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News